Back to top
more

DexCom (DXCM)

(Real Time Quote from BATS)

$76.92 USD

76.92
201,761

+0.37 (0.48%)

Updated Sep 17, 2025 10:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DexCom's (DXCM) strong product portfolio.

Zacks Equity Research

DexCom (DXCM) Stock Moves -0.12%: What You Should Know

by Zacks Equity Research

In the latest trading session, DexCom (DXCM) closed at $139.93, marking a -0.12% move from the previous day.

Zacks Equity Research

Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.

Zacks Equity Research

Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock

by Zacks Equity Research

UnitedHealth Group (UNH) remains well-poised for growth on the back of improved premiums, acquisitions and partnerships, an in-demand telehealth services suite and solid cash-generating abilities.

Zacks Equity Research

DexCom, Inc. (DXCM) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching DexCom (DXCM) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

DexCom (DXCM) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

DexCom (DXCM) closed at $134.17 in the latest trading session, marking a -0.41% move from the prior day.

Zacks Equity Research

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Zacks Equity Research

Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.

Nalak Das headshot

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Zacks Equity Research

Is It Worth Investing in DexCom (DXCM) Based on Wall Street's Bullish Views?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in DexCom (DXCM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare

by Zacks Equity Research

Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.

Bryan Hayes headshot

Medical Devices ETF Hits 52-Week High: Stocks to Watch

by Bryan Hayes

Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.

Zacks Equity Research

Roche (RHHBY) Launches AI-Based Predictive CGM Accu-Chek

by Zacks Equity Research

Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.

Zacks Equity Research

DexCom (DXCM) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

The latest trading day saw DexCom (DXCM) settling at $133.04, representing a -1.63% change from its previous close.

Zacks Equity Research

Community Health (CYH), Cost Plus Drugs Unite to Lower Drug Cost

by Zacks Equity Research

Community Health (CYH) collaborates with Cost Plus Drug to reduce drug costs and shortages.

Zacks Equity Research

DexCom's (DXCM) Direct-to-Watch Feature to Boost Its G7 System

by Zacks Equity Research

DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.

Zacks Equity Research

DexCom (DXCM) Soars 10% This Week: What's Fueling the Gain?

by Zacks Equity Research

A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.

Zacks Equity Research

Are Medical Stocks Lagging DexCom (DXCM) This Year?

by Zacks Equity Research

Here is how DexCom (DXCM) and Ambrx Biopharma Inc. (AMAM) have performed compared to their sector so far this year.

Zacks Equity Research

Investors Heavily Search DexCom, Inc. (DXCM): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to DexCom (DXCM). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

DexCom (DXCM) Soars 9.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

DexCom (DXCM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

DaVita (DVA) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

Zacks Equity Research

DaVita (DVA) Expands Operational Footprint Via New Agreement

by Zacks Equity Research

DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.

Zacks Equity Research

DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval

by Zacks Equity Research

DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.

Zacks Equity Research

DexCom (DXCM) Stock Moves -0.43%: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed at $121.78 in the latest trading session, marking a -0.43% move from the prior day.

Zacks Equity Research

DexCom (DXCM) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

In the most recent trading session, DexCom (DXCM) closed at $122.30, indicating a +0.46% shift from the previous trading day.